Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Marius M. Hoeper (Hannover, Germany), Marius Hoeper, Hossein-Ardeschir Ghofrani, Michael Halank, F. Joachim Meyer, Gerd Stähler, Jürgen Behr, Ralf Ewert, Monique Fletcher, Pablo Colorado, Sylvia Nikkho, Janethe de Oliveira Pena, Friedrich Grimminger. Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study. Eur Respir J 2015; 46: Suppl. 59, 4560

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Source: Eur Respir J 2010; 36: 792-799 Year: 2010 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Source: Eur Respir J 2015; 45: 1303-1313 Year: 2015 Chronic thromboembolic pulmonary hypertension (CTEPH) and beyond Source: Annual Congress 2011 - Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion) followed by Pulmonary Hypertension in the Clinic Grand Round - an interactive session Year: 2011 Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) Source: Eur Respir J 2015; 45: 1293-1302 Year: 2015 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Long-term outcomes of pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2007; 30: Suppl. 51, 603s Year: 2007 Prevalence of relapses and chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 A 1-year evolution of pulmonary artery pressure in the patients treated with various therapeutic methods after acute pulmonary embolism (PE). Its impact on the chronic thromboembolic pulmonary hypertension (CTEPH) development Source: Eur Respir J 2003; 22: Suppl. 45, 221s Year: 2003 Pregnancy and pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey Source: ERJ Open Res, 6 (4) 00520-2020; 10.1183/23120541.00520-2020 Year: 2020